Because the reduced Lrig1 expression increased the malignancy of low-grade diffuse glioma, we tested the complementary hypothesis, i.e., whether forced LRIG1 overexpression in human high-grade glioma cells (i.e., glioblastoma cells) can reduce their malignancy. The gene discussed is LRIG1; the disease is central nervous system cancer.